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Abstract
Background: Pulmonary-renal syndrome associated with anti-glomerular basement membrane (GBM) antibodies,
also known as Goodpasture’s syndrome, is a rare but acute and life-threatening condition. One third of patients
presenting as anti-GBM antibody positive pulmonary-renal syndrome or rapidly progressive glomerulonephritis are
also tested positive for anti-neutrophil cytoplasmic antibodies (ANCA). Whilst anti-GBM disease is considered a non-
relapsing condition, the long-term course of double-positive patients is less predictable.
Case Presentation: We report a patient with such dual positivity, who presented with pulmonary hemorrhage,
crescentic glomerulonephritis and membranous nephropathy. Plasmapheresis in combination with
immunosuppresive therapy led to a rapid remission but the disease relapsed after two years. The serum of the
patient was tested positive for antibodies to human lysosomal membrane protein 2 (hLAMP2), a novel autoantigen
in patients with active small-vessel vasculitis (SVV). The anti-hLAMP2 antibody levels correlated positively with
clinical disease activity in this patient.
Conclusion: We hypothesize that this antibody may indicate a clinical course similar to ANCA-associated vasculitis
in double-positive patients. However, this needs to be confirmed on comprehensive patient cohorts.
Background
Anti-GBM disease, also known as Goodpasture’s syn-
drome, is a paradigm for an autoimmune disease: The
antigenic epitope in the non-collagenous region of the
alpha 3 chain of type IV collagen [a3(IV)NC1] is well
defined, and the confined expression of this collagen to
glomerular and alveolar basement membranes leads to
the organ specificity of the disease [1]. In renal biopsies
linear positivity for immunoglobulin G (IgG) along the
GBM indicates the direct pathogenetic relevance of the
antibody. Interestingly, up to a third of patients with
anti-GBM disease are also positive for ANCA, mainly
with specificity to myeloperoxidase (MPO) [2-6]. This
latter antibody is commonly associated with microscopic
polyangiitis and to a lesser extent with granulomatosis
with polyangiitis (Wegener’s). Both are ANCA-positive
SVV with frequent renal involvement as crescentic glo-
merulonephritis without prominent Ig deposition
(pauci-immune CGN). The relatively high incidence of
such dual positivity indicates a pathogenetic link, which
still has to be unravelled. It is tempting to speculate on
ANCA-associated mechanisms leading to the exposure
of the otherwise hidden GBM-antigen [1,3]. Some
reports on a sequential positivity of ANCA followed by
anti-GBM antibodies support this hypothesis but other
reports also describe the opposite sequence [7-9]. Con-
troversies exist on the course of disease of double-posi-
tive patients. Older studies reported a favourable course
[10] but more recent reports conclude that renal prog-
nosis is comparable to anti-GBM disease [3,11]. Whilst
anti-GBM disease is generally considered a non-relap-
sing illness, ANCA-positive SVV has a relevant risk of
relapses demanding maintenance therapy after induction
of remission [12]. In double-positive patients both relap-
sing and non-relapsing courses of disease can be* Correspondence: clemens.cohen@usz.ch1Division of Nephrology, University Hospital Zurich, Zurich, Switzerland
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observed [5,6]. Therefore, an indicator for relapsing dis-
ease in double-positive patients is awaited.
This report summarizes our experience on diagnosis and
treatment of a patient with pulmonary-renal syndrome
(PRS), relapsing CGN with subepithelial immune deposits
and serological dual positivity for both anti-GBM antibo-
dies and MPO-ANCA, who was also tested positive for
novel SVV-associated antibodies against hLAMP2.
Case presentation
A non-smoking, 52-year-old woman presented to her
general practitioner with headache, fever and right-sided
thoracic pain. The chest radiograph showed a pulmon-
ary infiltrate of the right lower lobe. Antibiotic therapy
was initiated. Due to persistent fever a chest computed
tomography (CT) was performed two weeks later, which
showed low grade but diffuse ground-glass infiltration
beside previously described bronchiectasis. Alveolar
hemorrhage was documented by bronchoscopy. The his-
tologic examination of a lung biopsy showed alveolar
siderophages and focal chronic lymphocytic infiltration;
no immunofluorescence was performed. Consecutive
decline of kidney function completed the clinical picture
of a PRS and the patient was referred to a renal division.
Laboratory values at the time of referral are given in
Table 1. The serum tested positive for anti-GBM antibo-
dies as well as ANCA by standard indirect immuno-
fluorescence (ANA negative, anti-dsDNA 6 E/ml
(normal < 20)). Subsequent tests revealed antibody
reactivity against both, MPO and NC1 domain of type
IV collagen. A renal biopsy was performed and docu-
mented a necrotizing extracapillary proliferative glomer-
ulonephritis. There were nine glomeruli, one hyalinized,
with five mostly segmental crescents (two cellular, three
fibrocellular). A less well-preserved, frozen biopsy speci-
men did not show linear staining for human IgG by
direct immunofluorescence. Similarly, all other immuno-
globulins and complement factors were negative (IgA,
IgM, Kappa, Lambda, C3, C1q). This was surprising
since electron microscopy revealed small subepithelial
deposits of a membranous nephropathy stage 1, without
subendothelial or mesangial deposits (Figure 1, see
legend for details). The co-occurance of CGN and mem-
branous nephropathy is rare but has been described in
detail previously [13,14].
We concluded that the patient had double-positive
Goodpasture’s syndrome with falsely negative immuno-
fluorescence due to a not perfectly preserved frozen
biopsy specimen. Induction therapy was established with
plasma exchange, pulse cyclophosphamide and predni-
sone [12]. Anti-GBM titers became negative, MPO-
ANCA fell to 8 E/ml (normal < 5; Table 1). Cyclopho-
sphamide was stopped after three months but we
decided to pursue with maintenance therapy with
azathioprine because of the aforementioned findings
also consistent with SVV. However, on demand of the
patient prednisone was rapidly tapered and azathioprine
stopped after 15 months. Kidney function had recovered
to an estimated glomerular filtration rate of 50 ml/min.
Seven months after discontinuation of the maintenance
therapy the patient presented with mild dyspnea and
worsening kidney function as well as proteinuria and
microhematuria with dysmorphic erythrocytes. Anti-
GBM antibodies were found to be positive again (28 E/
ml) and rising MPO-ANCA were detected (56 E/ml,
Table 1). An initial chest CT showed regressive diffuse
small pulmonary infiltration, but no signs of acute pul-
monary hemorrhage. For the second time a kidney
biopsy was performed and showed a mostly global scler-
osing but also extracapillary proliferative glomerulone-
phritis again in combination with a membranous
nephropathy (detailed in the legend of Figure 2). Focal
interstitial fibrosis and tubular atrophy was also
observed. A global finely granular and a discreet seg-
mental linear IgG positivity was detected by immuno-
fluorescence in the GBM (Figure 1).
As this patient presented with the rare combination of
dual positivity for anti-GBM and MPO-ANCA with
relapsing pauci-immune CGN we examined the serum
at time of relapse for anti-hLAMP2 antibodies, a new
class of antibodies associated with SVV [15]. The serum
was indeed tested positive for anti-hLAMP2 antibodies.
This prompted us to test also archival serum samples of
Table 1 Laboratory results at initial presentation
(month -1), admission to hospital (month 0, time of first
renal biopsy), remission (month 1, 6, 12, 18), first relapse
(month 23, time of second renal biopsy), and under
therapy (month 25)
Time (months) -1 0 1 6 12 18 23 25
Renal Biopsy (no.) 1 2
Hemoglobin
[11.7 - 15.3 g/dl]
9.4 8.7 9.2 11.7 12.6 14.1 11 12.9
C-reactive protein
[< 5 mg/l]
84 13 2 < 3 < 3 < 3 < 3 < 3
Creatinine [44 - 80 μmol/l] 121 428 172 105 97 106 165 136
eGFR [> 60 ml/min] 41 10 27 48 53 48 29 35
Proteinuria [< 150 mg/d] n.a. 1700 n.a. 130 110 139 590 230
MPO-ANCA [< 5 units/ml] 121 58 7 8 13 19 53 10
Anti-GBM [< 10 units/ml] 130 68 9 2 n.a. n.a. 23 7
hLAMP-2 [units, see
legend]
n.a. n.a. 2 23 20 20 31 19
Normal values and units are given in squared bracket. eGFR = estimated
glomerular filtration rate according to MDRD formula, n.a. = not available.
For detection of hLAMP-2 antibodies archival sera for different time-points
were assayed. Briefly, the ELISA used human recombinant extracellular
domain expressed in E. coli as substrate and the results were expressed as
units derived from standard curve of a single strongly positive serum
(negative < 22, possible 22 - 28, positive > 28)
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this patient by enzyme-linked immunosorbent assay
(ELISA), immunfluorescence on cells stably expressing
hLAMP2 on the cell surface, and western blot (Table 1
and Figure 2). The serum concentration of anti-
hLAMP2 antibodies correlated positively with disease
activity (Table 1 and Figure 2). The lack of the typical
intense global linear IgG staining of the glomeruli com-
bined with rising antibody titers to MPO together with
the presence of anti-hLAMP2 antibodies led us to judge
the disease as relapsing ANCA-associated SVV; hence
plasmapheresis was discontinued and cyclophosphamide
with prednisone successfully reintroduced.
Figure 2 Detection of anti-hLAMP2 antibodies. A. The patient’s serum at time of relapse (month 23) was tested positive by indirect
immunfluorescence on ldlD cells stably expressing hLAMP-2 on the cell surface; whereas only minor staining was obtained during remission
(month 6). Results of the serum from a healthy, negative control and a positive SVV-control are shown in picture 1 and 2, respectively. B. The
serum was also tested positive by Western blot on E. coli expressed fusion protein. Lane 1-6: Serum of our patient at different time-points (one
major band corresponding to the fusion protein at around 66 kD). Lane 7: rabbit anti-hLAMP-2 polyclonal serum (positive control). Lane 8: anti-
human (negative control). All methods for detection of hLAMP-2 antibodies are published in detail elsewhere [15].
Figure 1 Renal biopsy findings. The first biopsy (corresponding to month 0 in table 1) showed cellular crescents (A) in two and fibrocellular
crescents (B) in three out of nine glomeruli, consistent with crescentic glomerulonephritis with moderate activity and moderate chronicity (Silver
methenamine stain; original magnification, (A) ×200, (B) ×180). The glomerular basement membrane revealed multiple small holes, no spikes.
Immunofluorescence study results were negative but on electron microscopy multiple small subepithelial deposits (arrows) indicative of membranous
nephropathy stage 1 were visible (C, original magnification, ×10.500). In the second biopsy (corresponding to month 23 in table 1) widespread global
sclerosis was present with sclerosis of 15 of 32 glomeruli and crescents in 5 glomeruli: two segmental fibrous crescents, two fibrocellular (one gobal
(arrow in D)), one segmental cellular crescent, with focal interstitial fibrosis and tubular atrophy, comprising 25% of the cortex, consistent with late
ANCA-associated sclerosing glomerulonephritis with minimal activity and severe chronicity (Silver methenamine stain; original magnification, (D) ×50,
(E) ×160). Immunofluorescence studies showed finely granular glomerular basement membrane positivity for IgG (2+) corresponding to the previously
diagnosed membranous nephropathy and a segmental linear (arrows) GBM positivity (F original magnification, ×280).
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Conclusion
So far, no conclusive maintenance therapy for patients
with dual antibody specificity for NC1 and MPO has
been established. This is at least in part due to the lack
of understanding the sequential events leading to the
development of both antibody types but, more impor-
tantly, due to failure to identify the disease defining
antibody that will, ultimately, determine progression and
outcome. Anti-hLAMP2 antibodies appear to indicate
active SVV and may thus serve as an indicator for relap-
sing disease also in patients with dual positivity. This
antibody reacts with an antigen expressed on endothelial
cells and neutrophils that shares complete homology to
the bacterial adhesin FimH [15]. It is reported to be pre-
sent in 90% of cases with active phases of ANCA-asso-
ciated necrotizing and crescentic glomerulonephritis and
was also seen in a small proportion of patients with
ANCA-positive Goodpasture’s syndrome [15].
Several characteristics of this patient led us to test her
serum for anti-hLAMP2 antibodies: First, Goodpasture’s
syndrome is considered a non-relapsing disease
[5,6,11,16]. In this patient the disease relapsed after a
clinical and serological remission. Second, two findings
in the renal biopsies are also suggestive for a SVV-like
disease: The initial biopsy did reveal different ages of
glomerular lesions (cellular and fibrocellular crescents,
detailed in the legend of Figure 1). This indicates a con-
tinuously evolving glomerulonephritis and not a sudden
and defined initiation. Such diverse glomerular altera-
tions are less common in acute anti-GBM disease [16].
The immunofluorescence of the initial kidney biopsy
was not positive and the subsequent biopsy showed
mostly a granular positivity for IgG corresponding to
the membranous nephropathy and only a segmental and
not the intense global linear positivity for IgG as in typi-
cal anti-GBM disease. In the literature most authors
report strong linear positivity for IgG in double-positive
patients [2,4,6], although a scanty positivity has also
been described in a subset of patients [3]. The membra-
nous nephropathy is another interesting aspect in our
patient. Although glomerular immune deposits are
found in about 50% of ANCA-associated CGN an iso-
lated subepithelial localisation of the immune complex
deposits is rarely observed. If present the combination
of membranous nephropathy and CGN appears to be
associated with high proteinuria and may accentuate the
clinical course of CGN [13,14].
We concluded that the clinical course and the histology
results are more suggestive for SVV than anti-GBM dis-
ease. This SVV-like course of disease can be seen in con-
junction with the positivity for anti-hLAMP2 antibodies.
One may hypothesize that the primary event is SVV with
glomerular and alveolar damage and subsequent
development of anti-GBM antibodies. However, this can
only be tested on serial serum samples taken before dis-
ease manifestation and cannot be concluded from a case-
report.
This case highlights the importance of testing for coex-
istence of different antibodies in patients with PRS, as it
may be a common manifestation of both SVV and Good-
pasture’s disease [5,6,17]. However, since the best long-
term treatment of double-positive patients is unknown,
an indicator for a relapsing SVV-like course of disease
would be helpful. Our case and its interpretation suggest
that anti-hLAMP2 antibodies may indicate a SVV-like
course of disease and therefore could be of clinical utility
for the management of double-positive patients. How-
ever, this needs to be tested on adequate patient cohorts.
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